Holen Sie sich die Stockscreener-App
263.96
0.02%
-0.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
AbbVie Stock Rises as Management Details Pipeline Momentum at Wells Fargo Healthcare Conference - TIKR.com
Why Did Billionaire Israel "Izzy" Englander More Than Double His Stake in AbbVie Stock and Start a Position in SpaceX Stock? - finance.yahoo.com
Diabetic Retinopathy Market Set for Strong Expansion Through 2036 Amid Rising Investment Interest – DelveInsight | Genentech, Ionis Pharma, AstraZeneca, Regenxbio, AbbVie, Palatin Techn, Avirmax Bio - Barchart.com
Endometriosis Market Analysis 2036: Industry Trends, Market Size, and Emerging Therapeutic Developments – DelveInsight | AbbVie, Kissei Pharma, Theramex, Hope Medicine, TiumBio, Viramal, Organon - Barchart.com
AbbVie Seeks To Nix Health Orgs' 'New Theory' In 340B Row - Law360
Can AbbVie (NYSE:ABBV) Defend Its Dividend Appeal? - Kalkine Media
Is AbbVie Stock Actually Overpriced? - Yahoo Finance
AbbVie’s ECLIPSE Migraine Trial Completes, Setting Up a New Catalyst for ABBV - TipRanks
AbbVie's Immunology Franchise: From Skyrizi & Rinvoq to What's Next - qz.com
Yarrow brings in more cash; AbbVie drug succeeds in menstrual migraine trial - Endpoints News
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s - Zacks Investment Research
What's Going On With AbbVie Stock Friday? - Benzinga
AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study - Yahoo Finance
AbbVie eyes extended Qulipta use case on Phase III menstrual migraine win - Yahoo Finance
AbbVie extends migraine leadership with positive Phase III atogepant results - thepharmaletter.com
AbbVie stock heads into the open after a 1.6% gain - ad-hoc-news.de
AbbVie declares $1.73 quarterly dividend payable Nov 16 to shareholders of record Oct 15 - Pluang
AbbVie, Eli Lilly Place Multi-Billion-Dollar Bets on Immunology Drugs in Race for Next Blockbuster - finance.biggo.com
AbbVie Declares Quarterly Dividend - Investing News Network
AbbVie Inc. stock outperforms competitors on strong trading day - MarketWatch
AbbVie Share Price Today (ABBV) | Live Chart, News & Stock Market - TechGraph
Abbvie Declares Quarterly Dividend, Payable on November 16, 2026 - marketscreener.com
AbbVie declares quarterly dividend of $1.73 per share - Investing.com
AbbVie declares quarterly dividend of $1.73 per share By Investing.com - Investing.com India
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
AbbVie Gains as Qulipta Opens a New Migraine Market - Yahoo! Finance Canada
AbbVie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine - Investing News Network
AbbVie reports positive Phase 3 migraine trial results - grafa.com
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days - Benzinga
AbbVie Inc. stock gains as atogepant trial success and HSBC target hike reinforce growth story - ad-hoc-news.de
ABBV Maintained by HSBC -- Price Target Raised to $315 - GuruFocus
AbbVie's menstrual migraine treatment meets late-stage study goal - Reuters
Why Has AbbVie Gone Quiet About Humira? - Trefis
ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie (Pending:ADRX) - Seeking Alpha
AbbVie’s migraine treatment meets late-stage study goal - 1450 AM 99.7 FM WHTC
AbbVie reports positive phase 3 trial for menstrual migraine drug By Investing.com - Investing.com Canada
No treatment is approved for menstrual migraine. AbbVie’s drug cut migraine days in a trial. - Stock Titan
UChicago Medicine names Kimyatta Washington Chief Operating Officer of AbbVie Foundation Cancer Pavilion | Newswise - Newswise
Here’s How Much You Would Have Made Owning AbbVie Stock In The Last 10 Years - Benzinga
Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth? - Yahoo Finance
AbbVie Highlights SKYRIZI, RINVOQ Growth and Pipeline Catalysts at Wells Fargo Conference - TradingView
AbbVie at Wells Fargo healthcare conference: growth beyond immunology By Investing.com - Investing.com UK
ABBV: Immunology, oncology, and neuroscience pipelines advance with strong data and strategic investments - TradingView
AbbVie stock slips as Q2 revenue rises 10.2 percent - ad-hoc-news.de
AbbVie issues US$10 billion to fund Apogee acquisition - fi-desk.com
AbbVie stock heads into the open after a 2.99 percent drop - ad-hoc-news.de
AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Apogee Therapeutics (NASDAQ: APGE) leaves Nasdaq in AbbVie cash buyout - Stock Titan
Why Did AbbVie (NYSE:ABBV) Just Close Its Biggest Deal In Years? - Kalkine Media
Is AbbVie Stock Too Reliant On Skyrizi? - Trefis
AbbVie Inc. stock edges lower as investors weigh strong earnings and higher analyst targets - ad-hoc-news.de
BofA Securities Upgrades AbbVie(ABBV.US) to Buy Rating, Raises Target Price to $282 - Moomoo
BofA Securities Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $282 - Moomoo
BofA raises Abbvie stock price target on Apogee deal close - investing.com
BofA raises Abbvie stock price target on Apogee deal close By Investing.com - Investing.com India
AbbVie’s Next Skyrizi Catalyst Lands This Fall. Here’s What’s at Stake for the Stock - TIKR.com
AbbVie Inc. (ABBV) Stock Analysis: Exploring Growth Potential Amidst A Solid 7.85% Upside - DirectorsTalk Interviews
What Does Friday’s Close Mean for AbbVie (NYSE:ABBV) and NYSE? - Kalkine Media
0.19%
1.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):